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SUMMARY  
Objective: To determine whether or not pre-donation 
testing of blood donors affords substantial cost savings 
without compromise to blood transfusion safety. Pre-
donation testing of blood donors for Transfusion 
Transmissible Infections (TTIs) is done in most devel-
oping countries because substantial cost savings are 
made from resources, materials and man-hours which 
would have been spent to procure infected blood units. 
Simple rapid test kits used in pre-donation testing is not 
as sensitive as the Enzyme Linked Immuno-sorbent 
Assay (ELISA) method used in post-donation screen-
ing in a quality assured manner. 
Design: It is a retrospective study where records of 
pre- and post-donation tests done in donor clinic of 
University of Ilorin Teaching Hospital, between Janu-
ary and December 2010 were retrieved. All processes 
and inputs were evaluated and costs calculated for pre-
donation testing by simple rapid techniques and post 
donation screening by ELISA.  
Results: 5000 prospective donors were tested in the 
study period. The cost of single rapid Pre-donation 
testing was less than that of single ELISA Post-
donation screen. The cost of double rapid Pre-donation 
and Post donation ELISA screen exceeded the cost of 
single post donation ELISA screen. Substantial cost 
savings were made when single rapid Pre-donation 
testing is relied on. More blood units were found reac-
tive for the TTIs with the more expensive Post-
donation ELISA.  
Conclusion: Pre-donation testing of blood donors was 
not cost effective. Although, there is an apparent sav-
ings if pre-donation testing is not followed by post-
donation ELISA testing, it is done at a compromise to 
blood transfusion safety.  
 






Pre-donation screening of blood donors for Transfusion 
Transmissible Infections (TTI) is the practice by which 
a prospective donor is tested for the presence of one or 
more of the TTI agents by a single rapid or quick 
method, and donation is deferred if the test is reactive 
for any of the TTI markers. Universally the normal 
procedure is to administer a standard questionnaire, 
measure the haemoglobin concentration and the weight 
of the donor1. The donor is then bled if found fit based 
on the selection criteria and asked to leave after a peri-
od of rest. The donor units are then separated into vari-
ous components and stored. A third generation ELISA 
batch analyzer is used to test samples of corresponding 
donated units. All those non-reactive for viral markers 
are appropriately labeled and used for transfusion. 
Those reactive for any of the TTIs are appropriately 
discarded, including their respective components. 
 
Hepatitis B virus (HBV), hepatitis C virus (HCV), 
Human immune deficiency virus (HIV) and syphilis 
are the most important agents causing transfusion 
transmitted infections (TTIs) and they constitute large 
health care burdens worldwide. Because of their latent 
nature prior to clinical presentation, their incidence 
rates are difficult to calculate.1 Every blood transfusion 
therefore carries a potential risk for transmissible dis-
eases.1,2 
 
The blood supply and transfusion practice in the United 
State is one of the safest in the world because they have 
been based on a combination of strategies including 
effective donor education and donor recruitment, and 
collection of blood from repeat voluntary donors, do-
nor retention, pre- and post-donation counseling, dona-
tion screening using the most sensitive and specific 
screening kits and recent laboratory procedures per-











Therefore, the risks of TTIs are extremely low3. It is 
estimated to be about 1 in 677,000 units of blood for 
HIV4, 1 in 103,000 units for hepatitis C virus and 1 in 
63,000 units for hepatitis B virus.3 
 
Various integrate measures are put in place to make 
blood transfusion safe. These measures include the 
recruitment of voluntary non-remunerated donors; ef-
fective donor education and careful donor selection; 
and the use of sensitive laboratory screening of donated 
blood.5 These measures together have resulted in a very 
low residual risk for TTIs.6 Comparable results for 
TTIs risks are found in most developed countries. In 
Australia the risks are 1 in 633,000 units for HBV, 1 in 
6,387,000 units for HCV and 1 in 9,242,000 units for 
HIV.7 
    
The objective of pre-donation TTI testing is to save 
resources, materials and man-hours which would have 
been spent to procure donor blood which could not be 
used in therapy and reduce the discard rate of donated 
blood. By performing pre-donation testing the infected 
prospective donor is spared the trouble of going 
through the donation process unnecessarily and the 
discard rate of donated blood is reduced. Pre-donation 
TTI testing is the standard practice in many Hospital-
based blood transfusion services in developing coun-
tries like Nigeria.  
 
A major consumable for blood collection is the import-
ed blood bag hence pre-donation testing and deferral of 
unsuitable prospective donor/s is assumed to produce 
substantial cost savings on procurement of blood bags. 
It appears however that the basis for such assumption 
has not been clearly established. All related financial 
costs and the implications for blood safety must be 
factored in to justify routine Pre-donation testing of 
blood donors. This study was carried out to establish 
whether or not Pre-donation testing affords substantial 
cost savings without compromise to blood safety. 
 
MATERIALS AND METHODS 
In the University of Ilorin Teaching Hospital, pre-
donation TTI testing is done after the prospective do-
nor has passed the haemoglobin check. Two rapid test 
systems are used to test for HIV, namely Determine 
and Unigold. The single rapid kit used for testing 
HBsAg is the ACON while Diaspot is used for testing 
HCV. Donation is deferred when the blood sample of a 
prospective donor is reactive for any of the TTI mark-
ers. Blood donated by donors found non-reactive on 
pre-donation TTI testing is later subjected in batches to 
routine Post-donation ELISA testing for the three TTI 
markers. 
 
All records of Pre and Post-donation tests carried out in 
the donor clinic of University of Ilorin Teaching Hos-
pital between January and December 2010 were re-
viewed. All processes and inputs were evaluated. Costs 
were calculated for Pre-donation testing by simple rap-
id techniques and Post-donation testing by ELISA for 
blood samples from all prospective donors. 
 
The compared costs were also computed for both Pre-
donation testing of all prospective donors and Post-
donation testing of blood samples of donors who even-
tually donated blood. All costs were compared. 
We also compared the number of samples that were 
reactive with rapid testing and the number that were 
reactive with ELISA. 
 
RAPID TEST KITS 
DETERMINE (Inverness Medical Japan Co. Ltd) is an 
immunochromatographic test for the qualitative detec-
tion of antibodies to HIV-1 and HIV-2. 
 
UNIGOLD (by Trinity Biotech Plc, Ireland) is a single 
reagent assay for the detection of antibodies to HIV-1 
and 2 in serum, plasma or whole blood. 
 
ACON (ACON Laboratories, Inc, San Diego, USA) is 
a qualitative, solid phase, two-site sandwich immuno-
assay for the detection of HBsAgs in whole blood, se-
rum or plasma. 
 
DIASPOT (Reagent by USA) is also a qualitative, 
membrane based immunoassay for the detection of 
antibody to HCV in serum or plasma. 
 
ELISA TEST KITS 
GENSCREEN PLUS HIV Ag-Ab (Bio-Rad, Raymond 
Poincare 92430, Marnes Coquettes and France) is an 
enzyme immunoassay for the detection of HIV infec-
tion, based on the detection of antibodies to HIV 1 and 
2 and the HIV 1 Ag in human serum or plasma. 
 
MONOLISA HBsAg ULTRA (Bio-Rad, Raymond 
Poincare 92430, Marnes Coquette, France) is a one-
step enzyme immunoassay based on the principle of 
the sandwich type using monoclonal antibodies and 
polyclonal antibodies selected for their ability to bind 
themselves to the various subtypes of HBsAg now rec-




 Approximately 5000 prospective donors presented at 
UITH donor clinic between January and December 
2010 and were tested. Eight hundred (800) of these 









Table 1 shows the unit costs of various inputs required 
for different testing methods for TTIs in Nigeria Naira 
(N) and in US Dollar ($). 
 
Table 1 Unit cost of various inputs required for simple 
rapid testing and ELISA screening at UITH. 
Cost of HIV simple rapid screen/unit by Deter-
mine 
N100 ($0.62) 
Cost of HIV simple rapid screen/unit by Uni-
gold 
N250 ($1.5) 
Cost of HBsAg simple rapid screen/unit N80 ($0.5) 
Cost of HCV simple rapid screen/unit N70 ($0.4) 
Cost of HIV ELISA/unit N945 ($5.7) 
Cost of HBsAg ELISA/unit N600 ($3.6) 
Cost of HCV ELISA/unit N600 ($3.6) 
Cost of Blood bag/unit N200 ($1.2) 
Cost of consumable/unit N100 ($0.6) 
 
Three million eight hundred and forty thousand naira 
(N3,840,000 ($23,040)) was the cost of pre-donation 
screening by rapid method for 5000 prospective do-
nors, Table 2.  
Twelve million eight hundred and forty nine thousand 
Naira (N12,849,000 (77,094)) was the total cost for 
pre-donation screen of the 5000 prospective donors in 
addition to post-donation ELISA testing of 4200 blood 
samples from respective donors who were found suita-
ble to donate, Table 2. 
 
Twelve million two hundred and twenty five thousand 
Naira (N12, 225,000 ($73,350)) was the total cost for 
ELISA testing without pre-donation screen of all the 
5000 prospective donors, Table 2. 
 
In UITH, approximately 75% of all donated blood is 
used on emergencies. Three million two hundred and 
sixty five thousand two hundred and fifty Naira (N3,  
265,250 ($19,592)) was the total cost for post-donation 
ELISA screening of samples of donated units remain-
ing after emergency use, Table 3 
 
 
Table 2 Total cost expended with simple rapid pre-donation testing only, simple rapid pre-donation testing plus 
ELISA and ELISA screening only. 
Simple rapid pre-donation testing of 
blood donors only 
Simple rapid pre-donation testing of 
blood donors  plus ELISA screen of 
donated blood units 
Pos-donation ELISA screen of donat-
ed blood units 
Procedure Amount N($) Procedure Amount N($) Procedure Amount N($) 
Pre-donation 









ELISA for 5000 
@ N2,145 ($13) 
N10,725,000 
($64,350) 
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  TOTAL N12,849,000 
($77,094) 
  
Table 3 Cost expended on post-donation ELISA screening of 800 donated units found reactive to pre-donation sim-
ple rapid testing and ELISA screening of units remaining after emergency use. 
Post-donation ELISA screening of 800 units found reac-
tive to simple rapid testing  
Post-donation ELISA screen of donated units remaining after 
emergency use 
Procedure Amount N($) Procedure Amount N($) 
ELISA for 800 @ N2,145 ($13) N1,716,000 ($10,296) ELISA for 1250 units @ N2,145 ($13) N2,681,250 ($16,088) 
Blood bags for 800 @ N200 ($1.2) N160,000 ($960) Blood bags for 4200 units @ N200 ($1.2) N84,000 ($504) 
Consumables for 800 @ N100 
($0.6) 
N80,000 ($480) Consumables for 5000@ N100 ($0.6) N500,000 ($3,000) 
TOTAL N1,956,000 ($11,736) TOTAL N3,265,250 ($19,592) 
 
 





From Table 2 it is obvious that an excess cost of six 
hundred and twenty four thousand Naira 
(N624,000($3,744)) was made when post-donation 
ELISA screen of all donated blood followed pre-
donation testing of all donors as compared with post-
donation screen of all donated blood only. Also an ap-
parent saving of nine million five hundred and eighty 
three thousand, seven hundred and fifty naira (N9, 
583,750 ($57,503)) was shown when approximately 
75% of all the donated blood were used as emergency 
without further ELISA screen on them. 
 
Eight hundred (800) out of 5000 samples (16%) were 
reactive with simple rapid testing for the TTIs 
[259(5.2%) for HIV 1and 2, 537(10.7%) for HBsAg 
and 4(0.08%) for HCV] while 850 (17%) [267(5.3%) 
for HIV1 and 2, 574(11.5%) for HBsAg and 9(0.2%) 
for HCV] eventually came out reactive with ELISA, 
 
DISCUSSION 
The result of this study shows that pre-donation testing 
of blood donors is not cost effective. For example, in 
order to save N160,000 ($960) on blood bags for the 
800 deferred donors, N2,520,000 ($15,120) was spent 
to screen, perhaps unnecessarily, the 4200 accepted 
donors. The alternative to pre-donation testing of blood 
donors is the post-donation screening of all donated 
blood by standard ELISA. The cost of ELISA testing 
for 5000 post donation samples is N12,225,000 
($73,350), compared to N3,840,000 ($23,040) for pre-
donation rapid testing of 5000 prospective donors. 
 
Thus, a huge sum of N9,583,750 ($57,503) is apparent-
ly saved if pre-donation simple rapid testing is not fol-
lowed by post donation ELISA testing of donated sam-
ples. When the cost of post-donation ELISA testing of 
blood samples of the 4200 accepted donors 
(N9,009,000 ($54,054)) is added to the cost of pre-
donation rapid testing of 5000 prospective donors 
(N3,840,000 ($23,040)), the total cost is N12,849,000 
($77,094). The cost of double rapid testing of donors 
and ELISA testing of donated samples exceeds the cost 
of single post-donation ELISA by N624,000 ($3,744), 
while only N160,000 (960) is saved on blood bags, 
giving a deficit of N464,000 ($2,784). 
 
It is therefore apparent that if any saving is to be made, 
it is done at an incalculable cost of compromise to 
blood safety when reliance is placed only on pre-
donation rapid TTI testing of blood donors. Our study 
further revealed that approximately 75% of donated 
blood is used for emergency transfusion before under-
going ELISA testing in our environment. This is what 
creates the false impression of savings by pre-donation 
testing of blood donors.  
This is not the best practice of blood transfusion, in 
which reliance is placed on only rapid screening of 
prospective donors. 
 
Literature comparing the total cost expended in pre- 
and post-donation testing for TTIs is very sparse, but 
several studies carried out have been for and against 
pre-donation TTI testing.8,9 Pre-donation testing has 
been found to be highly recommended in eliminating 
many potential risks for the donors, laboratory staff, 
blood recipients and their families and the overall soci-
ety in Pakistan.8 Another study in Ghana recognized 
the importance of post donation screening when up to 
3% of Hepatitis infected blood were tested positive 
with post donation sophisticated methods. In this study, 
they still recommended pre-donation testing of donors 
but with more sensitive and effective methods, donor 
screening with questionnaire before donation, donor 
information and counseling in high prevalence areas 
because the more sophisticated methods cannot be rou-
tinely available to all, in resource poor countries.9 
 
Consensus on blood transfusion practice is the same 
despite varying statistics from various researches all 
over the world. That is donors are the vital links in the 
chain of transmission of TTIs via blood transfusion. 
Therefore careful selection using designed question-
naire, proper screening of the blood (pre- or post-
donation) is the priority of all donations and overall 
transfusion services. With this, professionals in the 
field will be able to deliver safe end products. 
    
RECOMMENDATION 
 It is therefore recommended that pre-donation TTI 
testing be abolished, and all donated blood be tested by 
routine ELISA method. However, in order to accom-
modate emergency use of blood, simple rapid testing of 
donors for TTIs may be done pre-donation in addition 
to ELISA testing of donated blood which should still 
be carried out post-donation. Patients who may have 
been transfused with blood showing discordant results 
must then be followed up and managed accordingly. 
 
Apart from the financial loss incurred, pre-donation 
testing of blood donors is a form of inconvenience and 
time wasting to the prospective donor and can lead to 
discouragement of true voluntary donors. It should be 
mandatory to carry out the usual pre-donation selection 
using standard questionnaire and post donation screen-
ing of donated blood in all our blood banks. 
 
Family replacement donation, which is the main form 
of donation in resource poor countries like ours and 
which contributed to the high prevalence of TTIs, 
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